Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07834918

Pulmonary Hypertension and RV Dysfunction in Myeloproliferative Neoplasms

This cross-sectional study aims to determine the prevalence of pulmonary hypertension and right ventricular dysfunction in patients with myeloproliferative neoplasms and to identify associated clinical and hematologic factors.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Myeloproliferative Neoplasm Bone Marrow Diseases Cardiovascular Diseases Heart Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hypertension Hypertension, Pulmonary Lung Diseases Myeloproliferative Disorders Pulmonary Hypertension Respiratory Tract Diseases Right Ventricular Dysfunction Vascular Diseases Ventricular Dysfunction Ventricular Dysfunction, Right

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Myeloproliferative neoplasms (MPNs) are associated with an increased risk of pulmonary hypertension and right ventricular dysfunction. This observational study will include adults with confirmed polycythemia vera, essential thrombocythemia, or primary myelofibrosis.

All participants will undergo clinical assessment, laboratory evaluation, and echocardiography to assess pulmonary artery systolic pressure and right ventricular systolic function (TAPSE, FAC, and tissue Doppler S').

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • - Age 18 years or older
  • Confirmed diagnosis of myeloproliferative neoplasm (polycythemia vera, essential thrombocythemia, or primary myelofibrosis)
  • Stable clinical condition
  • Written informed consent

Exclusion criteria

  • - Significant left-sided valvular heart disease
  • Congenital heart disease
  • COPD or interstitial lung disease causing pulmonary hypertension
  • Poor echocardiographic window

Treatment and study plan

Primary outcomes

  1. Prevalence of Pulmonary Hypertension in MPN Patients

    Time frame: Baseline

    PASP measured by echocardiography using TR velocity. Pulmonary hypertension defined as PASP greater than 35 mmHg or TR velocity greater than 2.8 m/s. Prevalence will be calculated.

Secondary outcomes

  1. Prevalence of right ventricular dysfunction

    Time frame: Baseline

    Proportion of patients with right ventricular dysfunction defined by TAPSE <17 mm, RV fractional area change <35%, or tissue Doppler S' <9.5 cm/s

  2. Pulmonary artery systolic pressure

    Time frame: Baseline

    Mean estimated pulmonary artery systolic pressure (mmHg) measured by echocardiography

  3. Tricuspid annular plane systolic excursion (TAPSE)

    Time frame: Baseline

    Mean TAPSE value (mm) measured by echocardiography.

  4. Right ventricular fractional area change

    Time frame: Baseline

    Mean right ventricular fractional area change (%) measured by echocardiography.

Study contacts

Contact information is provided by the study sponsor or research team.

Esraa M Ahmed, Resident

CONTACT

[email protected]

+20 10 99071931

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Clinical and Hematologic Risk Factors of Right Ventricular Dysfunction and Pulmonary Hypertension in Myeloproliferative Neoplasms

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Sep 22, 2026
Registry last updated
Sep 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.